Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2024-01-30 Regulatory Filings
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
BIOS_PR_2024-01-30_ATO-Cu_Patent_Ca_FR_FINAL.pdf
Regulatory Filings Classification · 100% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE – INFORMATION PRIVILIGIEE" (Press Release – Privileged Information) and is dated 30/01/2024. It announces a specific corporate event: the granting of a patent in Canada for their ATO therapeutic platform. This type of announcement, which details a specific, material, non-financial event (like intellectual property news) released via a press release, fits best under the general category for regulatory announcements that are not specifically earnings, management changes, or dividend notices. Since it is a formal announcement of a significant development, and not a full financial report (like 10-K or IR), the most appropriate classification among the provided options is 'Regulatory Filings' (RNS), as it serves as a general regulatory disclosure for material, non-standard events. It is not an Earnings Release (ER), Interim Report (IR), or a specific management/governance document. It is a disclosure of IP news.
2024-01-30 French
BioSenic_Rapport_spécial_CA_Art_7198_juncto_7180_7191_7193_20240116.pdf
Capital/Financing Update Classification · 95% confidence The document is a special report from the Board of Directors prepared in accordance with specific articles of the Belgian Code of Companies and Associations (CSA). It details the proposal for the issuance of new convertible bonds within the authorized capital framework, including the justification, terms, subscription agreement, and financial consequences for shareholders. The report is not a full annual or interim financial report but a detailed board report concerning a capital increase and financing operation. It is not a simple announcement or certification but a substantive report prepared by the board to inform shareholders and comply with legal requirements regarding capital increases and convertible bond issuance. This fits the category of Capital/Financing Update (CAP) as it focuses on fundraising and capital structure changes through convertible bond issuance.
2024-01-16 French
BIOS_PR _Phebra licensing and MDA on cGvHD _EN_Final.pdf
Regulatory Filings Classification · 100% confidence The document is explicitly titled "PRESS RELEASE – INSIDE INFORMATION" and dated 15/01/2024. It announces a significant business event: reaching an agreement on a binding term sheet with Phebra PTY Ltd. regarding the development and commercialization terms for OATO. This type of announcement, detailing strategic business developments, licensing changes, and financial implications, is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a press release detailing key operational and financial agreement changes, it fits best under the Earnings Release (ER) category, which often includes material business updates alongside or instead of pure financial figures, or potentially a Regulatory Filing (RNS) if it were less focused on immediate business impact. Given the content focuses on a major agreement update, ER is a strong candidate, but since it's not explicitly reporting quarterly/periodical financial results (like revenue/net income), and is more of a strategic business update, it aligns closely with the nature of an Earnings Release announcement or a general regulatory filing. However, the content is a major corporate development announcement, which often accompanies or substitutes for a formal ER in biotech/pharma. Since it is a 'Press Release' announcing a major strategic agreement, and not a full financial report, it is classified as an Earnings Release (ER) as it serves to inform the market of material, time-sensitive information, or as a Regulatory Filing (RNS). Given the specific nature of the announcement (licensing/term sheet), and the lack of a specific category for 'Strategic Partnership Announcement', ER is chosen as the closest fit for a market-moving announcement, though RNS is also plausible. Upon review, the content is a major corporate development announcement, which is often categorized under ER if it's market-moving, or RNS if it's a general regulatory disclosure. Since it is a 'Press Release' and not a formal financial statement, and it details a significant business transaction, ER is the most appropriate fit among the provided options for a market-moving announcement.
2024-01-15 English
BIOS_PR _Phebra licensing and MDA on cGvHD _FR_Final.pdf
M&A Activity Classification · 99% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE – INFORMATION PRIVILIGIEE" (Press Release – Privileged Information) and is dated 15/01/2024. It announces a significant business event: BioSenic concluding an agreement with Phebra PTY Ltd. regarding the development and licensing terms for a drug (OATO). This type of announcement, detailing strategic business developments, licensing changes, and financial implications, is characteristic of a general corporate announcement or press release. Since the document is a formal announcement of a material event rather than a full periodic financial report (like 10-K or IR), a capital structure change (CAP), or a management change (MANG), the most appropriate classification is a general Regulatory Filing (RNS), which serves as a broad category for material, non-standardized announcements, or potentially a Capital/Financing Update (CAP) due to the focus on licensing and revenue allocation, but RNS is safer for a general press release announcing a deal. Given the content is a press release announcing a major licensing/commercialization agreement update, it fits best under the general regulatory announcement category (RNS) as it is not a specific financial report, earnings release, or management change announcement. It is not short enough to strictly qualify as an RPA based on the 'Menu vs Meal' rule, as it contains substantial detail about the agreement terms.
2024-01-15 French
BIOS_PR_2024-01-15_Transparency Notification_Multiple_EN_Final.pdf
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "PRESS RELEASE – REGULATED INFORMATION" and details transparency notifications received regarding changes in shareholdings by an individual named François Rieger, specifically mentioning the crossing of a major holding threshold (15%) under Article 14 of the relevant law. This content directly relates to insider transactions or significant ownership changes, which aligns perfectly with the definition of Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Since the core subject is the notification of a change in a major holding threshold (crossing below 15%), the most precise classification is Major Shareholding Notification (MRQ). It is not a general Earnings Release (ER), a full Annual Report (10-K), or a proxy statement (DEF 14A/PSI).
2024-01-15 English
BIOS_PR_2023-10-16_Transparency Notification_Multiple_FR_Final.pdf
Major Shareholding Notification Classification · 99% confidence The document is titled "COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE" (Press Release - Regulated Information) and announces the receipt of transparency notifications from an individual (François Rieger) regarding changes in their shareholding percentage, specifically crossing a passive threshold of 15% following a new share issuance. This type of filing, which reports personal share transactions by executives or major shareholders crossing regulatory thresholds, directly corresponds to the definition of Director's Dealing (DIRS) or, more broadly, Major Shareholding Notification (MRQ). Since the content explicitly details the notification of a change in significant share ownership (crossing the 15% threshold), MRQ (Major Shareholding Notification) is the most precise fit, although DIRS often covers insider trades, MRQ covers the notification of crossing ownership thresholds. Reviewing the definitions: - DIRS: Report of personal share transactions by company directors and executives (insider trades). - MRQ: Notification of changes in significant share ownership levels (crossing thresholds). The document focuses on the notification of crossing a specific ownership threshold (15%) by a major shareholder, making MRQ the most accurate classification.
2024-01-15 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.